patienc test
miss reset
afternoon pre-announc earn miss
test patienc thesi obvious magnitud miss disappoint
appear full reset revenu outlook announc
frustrat check across popul sequenc clinic
suggest demand view debat matter
ultim would look add major disloc reiter ow
rate said lower pt given new baselin
preliminari revenu well expect guidanc
specif expect report revenue
estim impli growth y/i vs forecast/guid y/i illumina
attribut revenu miss popul sequenc
direct-to-consum dtc market nextseq under-perform
silver line novaseq system shipment ahead expect
consum appear spot forecast provid
updat ep expect note would provid detail
earn call given lower top line potenti margin compress pencil
adj ep miss versu prior visibl admittedli low
weaker trajectori reset expect given
underli fund transitori natur issu believ new
guidanc could prove conserv project revenu growth
approxim previou guidanc compani
provid updat ep guidanc earn lower forecast
prior forecast new forecast repres
growth y/i revenue growth visibl low learn cost action
taken encourag manag thought around ensur cost
action inhibit compani innov commerci effort
lower usd
return equiti ttm
link barclay live interact chart
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight leader next
gener sequenc project
signific growth driven larg research studi
nascent opportun clinic diagnost
signific competit moat rel
competit given brand scale
growth forseeabl futur
compani instal base grow higher
consum revenu contribut margin
leverag estim upsid case
reflect upsid ep
growth ultim depend
custom fund includ govern grant
nih well clinic reimburs lower
downsid case reflect downsid
ep
afternoon pre-announc earn miss test
patienc thesi repres fourth pre-announc track go
back revenu miss worst record obvious magnitud
miss disappoint appear full reset outlook
announc frustrat channel check across popul
sequenc clinic suggest demand continu view
debat matter
ultim would look add major disloc reiter
overweight rate said lower price target given
new baselin price target repres pro-forma adj ep
estim stand-alon estim adjust estim potenti
pac-bio dilut prior price target repres prior pro-forma
estim stand-alon estim adjust potenti pac-bio
note preliminari revenu well expect
guidanc specif expect report revenu
estim result impli growth y/i vs forecast guidanc
y/i attribut revenu miss sever factor
popul sequenc roughli versu compani intern forecast
revenu popul sequenc initi came lower impact
sizabl system consum order slip origin expect
second half june
 direct-to-consum dtc market attribut
miss on-going weak direct-to-consum dtc market primarili
impact compani array busi compani previous cautiou
around dtc market embed lsd growth declin believ
updat impli market deterior
 nextseq under-perform instrument line grew q/q y/i
revenu fell short expect compani nextseq
pull-through line recent rais guidanc rang
silver line underli novaseq system shipment ahead
expect consum appear spot forecast expect
report novaseq consum volum growth q/q y/i strength
driven flow cell level novaseq consum growth line
estim y/i compani note outsid
aforement popul sequenc order headwind novaseq shipment ahead
expect quarter
provid updat ep expect note would
provid detail earn call juli given lower top line
expect compani take cost action think margin
compress like quarter pencil adj ep would
repres miss versu prior estim although visibl low
context miss top line yield miss adj ep
revenu miss lead guidanc reset
weaker trajectori reset expect given
underli fund across popul sequenc clinic adopt coupl
transitori natur issu believ new guidanc could prove
conserv project revenu growth approxim
previou guidanc revenu reset attribut
conserv outlook dtc ramp popul genom well lower
non-high-throughput sequenc system consum embed guidanc
growth sequenc revenu includ sequenc consum growth
slight y/i declin sequenc servic previous guid mid-
teen sequenc revenu sequenc consum growth given dtc
test weak array revenu anticip declin y/i roughli
flat april guidanc posit novaseq pull-through still expect higher
shipment platform expect flat slightli y/i
line previou guidanc
compani provid updat ep guidanc offici earn
releas juli given lower revenu trajectori expect
margin compress lower forecast prior forecast
new forecast repres growth y/i revenu growth
admittedli visibl low learn cost action compani take
encourag manag thought around ensur cost action inhibit
compani innov commerci effort
y/i y/i y/i stack y/i product y/i y/i y/i product servic y/i array y/i y/i y/i consum instrument barclay illumina inc
estestestestestestestincom statement growth growth growth growth growth growth y/i growth product revenu ex product revenu inc product revenu inc servic servic gross gross margin inc gross margin inc growth gener growth base sg stock base opex ebitda growth oper incom ebit growth invest debt expens pre-tax pre-tax growth incom tax non-control interest net adj net growth growth net net barclay illumina inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
